PAM-2
PAM-2 is a potent, orally active, CNS-penetrant selective α7 nAChR positive allosteric modulator (human α7 nAChR EC50: 39 μM, rat α7 nAChR EC50: 12 μM) with anti-nociceptive and anti-inflammatory activity. PAM-2 exhibits selectivity over α9α10 nAChR (IC50 = 174 μM) and CaV2.2 channel (IC50 = 89 μM). PAM-2 decreases Streptozotocin (STZ) (HY-13753)- and Oxaliplatin (HY-17371)-inducned nuroparhic pain in mice by α7 nAChR potentiation. PAM-2 can be used for the research of neuropathic pain.
For research use only. We do not sell to patients.
- CAS No.: 1426293-61-9
- Formula: C14H13NO2
- Molecular Weight:227.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Calcium Channel Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
human α7 nAChR 39 μM (EC50) |
rat α7 nAChR 12 μM (EC50) |
CaV2.2 89 μM (IC50) |
α9α10 nAChR 174 μM (IC50) |
In Vitro
PAM-2 (0.3 μM-1 mM; 5 min) potentiates Ach (30 μM)-activated α7 nAChRs in Xenopus oocytes in a concentration-dependent manner[1].
PAM-2 (0.3 μM-1 mM; 2 min) inhibits ACh (10 μM)-evoked currents at rα9α10 nAChRs in Xenopus oocytes in a concentration-dependent and voltage-independent manner[1].
PAM-2 (0.3 μM-1 mM) inhibits Cav2.2 channel-mediated Ba2+ currents without affacting G protein-coupled GABABR in HEK293 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
PAM-2 (1 mg/kg; p.o; coadministered with Oxaliplatin schedule for 14 days; and an extra dose 30 min post last co-treatment) prevents pain establishment when combined with Oxaliplatin, and increases pain threshold in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male CD-1 albino mice (2-3 months old) intraperitonealy injected with STZ (100 mg/kg)[1]
-
Dosage:1, 3 mg/kg
-
Administration:p.o.; single dose on day 15 post-STZ
-
Result:Significantly decreased neuropathic pain between 15 and 45 min at 3 mg/kg, 45 min, with complete reversal at 30 min.
Showed no effect at 1 mg/kg.
-
Animal Model:Male CD-1 albino mice (2-3 months old) intraperitonealy injected with Oxaliplatin (2.4 mg/kg) on days 1-3, 6-10, and 13-14[1]
-
Dosage:1, 3 mg/kg
-
Administration:p.o.; single dose on day 15 post-Oxaliplatin
-
Result:Significantly decreased neuropathic pain from 15 to 45 minutes after administration, with peak reversal at 30 min at 3 mg/kg.
Showed no effect at 1 mg/kg.
-
Animal Model:Male CD-1 albino mice (2-3 months old) intraperitonealy injected with Oxaliplatin (2.4 mg/kg) on days 1-3, 6-10, and 13-14[1]
-
Dosage:1 mg/kg
-
Administration:p.o; coadministered with oxaliplatin schedule for 14 days; and an extra dose 30 min post last co-treatment
-
Result:Prevented pain establishment by day 14.
An additional administration on the test day produced greater pain reversal within 0-30 min.
Chemical Information
-
CAS No. 1426293-61-9
-
Molecular Weight 227.26
-
Formula C14H13NO2
-
SMILES
N(C(/C=C/C1=CC=CO1)=O)C2=CC=C(C)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)